MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.

Trial Details

NCT Number	NCT06596746
Lead Sponsor	Casa di Cura San Raffaele Cassino Collaborators: IRCCS San Raffaele Roma, San Raffaele Telematic University, University of Urbino "Carlo Bo", University of Cassino and Southern Lazio, University of Roma La Sapienza, Politecnico di Milano
Conditions (from sponsor)	Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease, Multiple System Atrophy, Tauopathies, Alzheimer Disease, Corticobasal Degeneration +10 more
Related terms	Alzheimer Disease, Amyotrophic Lateral Sclerosis, Cognitive Dysfunction, Corticobasal Degeneration, Dementia, Frontotemporal Lobar Degeneration, Iron Overload, Lewy Body Disease, Movement Disorders, Multiple System Atrophy, Neurodegenerative Diseases, Pantothenate Kinase-Associated Neurodegeneration, Parkinson Disease, Supranuclear Palsy, Progressive, Synucleinopathies, Tauopathies, TDP-43 Proteinopathies
Enrollment	600 participants
Start Date	Sep 9, 2024
Primary Completion	Sep 9, 2034 (estimated)
Study Completion	Sep 9, 2034 (estimated)
Updated on ClinicalTrials.gov	Sep 2, 2026